The nasal vaccine -- BBV154 -- had received Drugs Controller General of India's approval in November for restricted emergency use among adults...

I have not done anything wrong, says Maiden Managing Director Naresh Kumar Goyal...

DGCI accuses WHO of relying on a 'premature deduction'...

The committee will recommend further course of action to the Drugs Controller General of India after examining and analysing the adverse event reports...

Development comes on a day the Haryana government ordered the halting of drug manufacturing at the Sonipat unit of Maiden Pharmaceuticals...

India's drug regulator Drugs Controller General of India has already initiated a probe and sought further details from the World Health Organisation...

Currently, only one vaccine against malaria is available globally and GSK is the manufacturer of that...

The Hyderabad-based firm completed clinical trials of the nasal vaccine with about 4,000 volunteers and there is no side effect or adverse reaction reported so far...

The Drugs Controller General of India also gave restricted emergency use authorisation to Corbevax for those aged 5 to 12 years...

The Subject Expert Committee has sought more data from Bharat Biotech to review its EUA application for the use of Covaxin in the 2-to-11 age group...